The stock may react negatively to the EPS miss and dilution, but the financing secures funding through the pivotal 2027 data readout, reducing near-term liquidity risk, monitor enrollment progress and upcoming trial updates.
ANVS drugs
ANVS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 10 $1.59entry
- T+1 · 7mo ago +4.40%α +3.43% · $1.66
- T+5 · 7mo ago +17.61%α +13.11% · $1.87
- T+20 · 6mo ago +42.14%α +33.61% · $2.26
- T+60 · 4mo ago +20.75%α +10.43% · $1.92
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Annovis Bio reported a wider-than-expected EPS loss of $-0.39 (vs $-0.36 est) with no revenue, but secured $10M in gross proceeds from a public offering, extending its cash runway to Q2 2027 and fully funding its path to a Phase 3 Alzheimer's data readout and NDA submission for buntanetap.
Key Financial Metrics
Key Facts
- Reported EPS of $-0.39, missing consensus by $-0.03 (-8.3%)
- No revenue reported for the period
- Closed $10M underwritten public offering, extending cash runway to Q2 2027
- Alzheimer's Phase 3 trial 75% enrolled; 6-month symptomatic data readout expected Q1 2027
- FDA to accept integrated safety data from both AD and PD trials for NDA submission
- Parkinson's open-label study 28% enrolled since February 2026
Financial Impact
Dilutive offering of $10M at a loss-making stage; EPS miss of 8.3% but cash secured for key milestones
Risk Factors
- Dilution from $10M public offering
- No revenue and continued losses; dependence on trial outcomes
- Clinical trial delays or negative data could derail NDA timeline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3271713 |
Track record
19 reports on ANVS
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +19.53% at T+20 after the May 20, 2026 report. 4 of 10 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 5/10 Entry $0.9261 Now $0.7500 −19.02% settles Feb 11
- Nov 5, 202611d ago 8-K Bearish 7/10 Entry $0.8449 Now $0.7500 +11.23% settles Feb 4
- Nov 5, 202611d ago 424B5 Bearish 7/10 Entry $0.8449 Now $0.7500 +11.23% settles Feb 4
- Nov 5, 202611d ago Press Release Bearish 7/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Nov 4, 202612d ago 424B5 Bearish 6/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Nov 4, 202612d ago Press Release Bearish 7/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Nov 4, 202612d ago 8-K Bearish 7/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Oct 30, 202617d ago 8-K Bearish 7/10 Entry $1.08 Now $0.7500 +30.56% settles Jan 29
- Oct 19, 202628d ago 8-K Neutral 1/10 Entry $0.9783 Now $0.7500 −23.34% settles Jan 15
- Oct 15, 20264w ago SC 13G/A Neutral 3/10 Entry $1.05 Now $0.7500 −28.57% settles Jan 12
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers